Compare JXG & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JXG | RANI |
|---|---|---|
| Founded | N/A | 2012 |
| Country | China | United States |
| Employees | 95 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.9M | 106.9M |
| IPO Year | N/A | 2021 |
| Metric | JXG | RANI |
|---|---|---|
| Price | $10.10 | $0.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 5.1K | ★ 855.1K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,633,000.00 |
| Revenue This Year | N/A | $274.77 |
| Revenue Next Year | N/A | $79.44 |
| P/E Ratio | $0.77 | ★ N/A |
| Revenue Growth | N/A | ★ 58.85 |
| 52 Week Low | $0.23 | $0.39 |
| 52 Week High | $11.80 | $3.87 |
| Indicator | JXG | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 75.18 | 41.91 |
| Support Level | $3.57 | $0.71 |
| Resistance Level | N/A | $1.05 |
| Average True Range (ATR) | 0.68 | 0.05 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 72.03 | 28.67 |
JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products. The Company's operations are located in the PRC and all of the Company's revenue is derived from sales to customers in the PRC region.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.